Inside the Beltway: FDA orders section 522 post-market studies for duodenoscopes Oct. 6, 2015 By Mark McCarty No Comments
'Uphill battle' predicted by attorney for off-label issues in Senate Cures bill Oct. 2, 2015 By Mark McCarty No Comments
Inside the Betltway; FDA Warns Firm Device processing carries definite QS compliance Liabliiy Oct. 1, 2015 By Mark McCarty No Comments
Inside the Beltway: Survey hints that industry is largely unaware of EF guidance Sep. 30, 2015 By Mark McCarty No Comments
Inside the Beltway: FDA staff report 'upsurge' in U.S. early feasibility studies Sep. 29, 2015 By Mark McCarty No Comments
New Leader yet to be named: Ubl leaving AdvaMed and med-tech to become new CEO at PhRMA Sep. 28, 2015 By Mark McCarty No Comments
Hawkins sees coverage as biggest entry barrier to med-tech market Sep. 28, 2015 By Mark McCarty No Comments
Inside the Beltway: AdvaMed: IDE benefit-risk draft's use of 'well-designed' term too squishy Sep. 25, 2015 By Mark McCarty No Comments